Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Tirzepatide (Zepbound) Approved for Chronic Weight Management

    Tirzepatide (Zepbound) Approved for Chronic Weight Management

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    Start listeningView podcast show

    Tirzepatide (Zepbound) Approved for Chronic Weight Management

    FromDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

    ratings:
    Length:
    15 minutes
    Released:
    Nov 8, 2023
    Format:
    Podcast episode

    Description

    In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.
    Released:
    Nov 8, 2023
    Format:
    Podcast episode

    Titles in the series (94)

    Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.